Biology of the malignant plasma cell

2004 ◽  
pp. 58-73 ◽  
Author(s):  
Federico Caligaris-Cappio
1993 ◽  
Vol 30 (6) ◽  
pp. 505-511 ◽  
Author(s):  
K. S. Frazier ◽  
M. E. Hines ◽  
A. I. Hurvitz ◽  
P. G. Robinson ◽  
A. J. Herron

To derive a method for determining malignant potential of plasma cell tumors, a retrospective analysis of the DNA ploidy and relative p62c-myc oncoprotein content using bivariate flow cytometry was performed on 23 formalin-fixed, paraffin-embedded tissues from 23 dogs. The samples included one tissue each from 17 males and six females 2 to 16 years of age (mean = 7.5 years). Twelve breeds were represented, including three Cocker Spaniels, three Golden Retrievers, and five of mixed breed. Ten of the samples were histologically classified as malignant-plasma cell tumors, and ten specimens were classified as benign. Three samples of plasmacytic inflammation, from two Cocker Spaniels and one Shih Tsu, were included as controls. The ploidy and relative c-myc content data obtained were compared with the histologic grade. A significant difference in ploidy was found between benign and malignant tumors (P ≤ 0.05). Five of nine malignant plasma cell tumors were aneuploid; the remainder were diploid (4/9) or tetraploid (1/9). Only one of the benign plasmacytomas was aneuploid (1/10), whereas six were diploid (6/10), and three were tetraploid (3/10). All of the controls were diploid (3/32). When relative amounts of p62c-myc from malignant and benign tumors were compared by flow cytometry, a greater significant difference was established (P ≤ 0.01) than by using aneuploidy alone. Relative values of p62c-myc content ranged from 219 to 553 units in 8/10 malignant plasma cell tumors and from 86 to 392 units in 3/10 benign plasmacytomas. The remainder of the neoplasms (2/10 malignant and 7/10 benign) lacked measurable values of p62c-myc above background fluorescence concentrations. Two atypical cutaneous plasmacytomas with later metastasis were included in the study. The results indicate that simultaneous analysis of ploidy and relative p62c-myc concentration can be used as an aid in assessment of malignant potential in canine plasma cell tumors.


Leukemia ◽  
2014 ◽  
Vol 29 (2) ◽  
pp. 474-482 ◽  
Author(s):  
Y Hu ◽  
W Song ◽  
D Cirstea ◽  
D Lu ◽  
N C Munshi ◽  
...  

Leukemia ◽  
1998 ◽  
Vol 12 (4) ◽  
pp. 610-618 ◽  
Author(s):  
X-G Zhang ◽  
D Olive ◽  
J Devos ◽  
C Rebouissou ◽  
M Ghiotto-Ragueneau ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 990-990 ◽  
Author(s):  
Alexander L. Kovalchuk ◽  
Elizabeth Mushinski ◽  
Brad Burkholder ◽  
Chen-Feng Qi ◽  
Zhaoyang Li ◽  
...  

Abstract Consistent with the role of activation induced cytidine deaminase (AID) as a major “catalyst” of aberrant translocations between the Ig switch regions and c-myc, AID-sufficient Bcl-xL transgenic mice rapidly develop transplantable plasmacytomas with classical T(12;15) translocations. Unexpectedly, we found that Bcl-xL transgenic BALB/cAn mice deficient for AID (designated pBxAicda−/− mice) also developed plasma cell tumors but with a lower frequency (24% vs. 62%) and with a longer mean latency (108 d vs. 36 d) than AID-sufficient controls. Six out of nine of primary tumors were shown by interphase FISH to contain a T(12;15) translocation and one other had a T(6;15). pBxAicda−/− tumors did not transplant well because they were presumably in early stages of neoplastic development or had not progressed to full malignancy including association with ascites. Nevertheless, two tumors (4885 and 4961) were successfully transplanted and established as stable cell lines. They exhibited mature plasma cell phenotype (CD45−, CD138+, PC-1+, CD19−, CD23−) and secreted IgM. Gene expression profiling showed no significant difference from control plasma cell tumors of AID-sufficient mice. Detailed molecular and cytogenetic analysis of 4885 uncovered an unusual unbalanced T(12;15) translocation with IgH Cμ and Pvt-1 in a head to tail orientation at the breakpoint, resulting in elevated c-myc expression as detected by qPCR. In contrast, 4961, a T(12;15) negative cell line, had elevated N-myc expression as a result of paracentric inversion of Chr. 12. These rearrangements had no direct association with RAG activity. We conclude that rapid development of malignant plasma cell tumors with reciprocal T(12;15) does require AID, and that in AID deficiency a novel less efficient mechanism can be utilized to bring c-myc and Ig genes into juxtaposition.


Cancer ◽  
1990 ◽  
Vol 66 (2) ◽  
pp. 363-368 ◽  
Author(s):  
Jay E. Gold ◽  
Lori Schwam ◽  
Antonio Castella ◽  
Sheldon B. Pike ◽  
Richard Opfell ◽  
...  

2020 ◽  
Vol 51 (4) ◽  
pp. 193-202
Author(s):  
Artur Jurczyszyn ◽  
Ruth Hutch ◽  
Anna Waszczuk-Gajda ◽  
Anna Suska ◽  
Katarzyna Krzanowska ◽  
...  

AbstractMonoclonal gammopathy of undetermined significance (MGUS) is a clonal plasma cell disorder implicated as a precursor of multiple myeloma (MM), while smoldering multiple myeloma (SMM) is a malignant plasma cell disorder without evidence of a myeloma-defining event(s) (MDE). This is a review article of both disorders outlining their current definition and management according to the current standard of care. We focus on the pathogenesis of MM and the role of MGUS and SMM in the development of active MM. MGUS is a benign disorder and, subsequently, is followed by observation. In contrast, for SMM, although the current standard of care is “watch and wait”, this paper will explore the circumstances in which treatment should be considered to prevent MDE.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4808-4808
Author(s):  
Shuang Geng ◽  
Jing Wang ◽  
Mingyi Chen ◽  
Wenming Wang ◽  
Yuhong Pang ◽  
...  

Abstract Extramedullary Plasmacytoma (EMP) is a minor yet devastating metastatic form of Multiple Myeloma (MM), shortening patients' survival from 10 years to 6 months on average. Genetic cause of EMP in MM is yet to be defined. Transcriptome difference between EMP+ patients and EMP- patients is studied here on single cell level by RNA Sequencing (RNA-Seq). We sorted CD38+CD138+ malignant plasma cells from bone marrow and peripheral blood samples by flow cytometry, then picked up single malignant plasma cell and performed single cell RNA-Seq with SmartSeq2 protocol followed by Tn5-based library preparation from bone marrow, peripheral blood and extramedullary tissue of EMP patients. From the single cell RNA-Seq results, in bone marrow we found differential gene expression between EMP+ and EMP- samples, such as CTAG2, STMN1 and RRM2. By comparing circulating malignant plasma cells in PBMC and malignant plasma cell from the sample EMP+ patient, we observed metastatic clone in blood with the same VDJ immunoglobulin heavy chain as in bone marrow. Several genes' expression of these metastatic cells are down-regulated than in bone marrow, such as PAGE2, GTSF1, DICER1. These genes may correlate with egress capability of MM cells into peripheral to become circulating plasma cells (cPCs), and EMP eventually. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document